Bromocriptine, a dopamine antagonist that inhibits prolactin secretion prevented the expected deterioration in the size of the left ventricle and systolic function when given in addition to standard heart failure therapy in women with PPCM.
Timed daily administration of
bromocriptine to reestablish the daily peak in SCN dopaminergic activity also reverses the VMH and PVN abnormalities described above [30, 37, 46] and improves postprandial insulin resistance (even via its intracerebroventricular administration) [26, 30, 45].
Long-acting injectable
bromocriptine does not reduce relapse in alcoholics.
The second review, of 7 trials with a total of 1100 patients, compared
bromocriptine plus levodopa with levodopa alone.
Daily treatment of insulin resistant/glucose-intolerant animals with appropriately time-pulsed systemic or intracerebroventricular administration of the dopamine D2 receptor agonist
bromocriptine to increase hypothalamic dopaminergic tone improves insulin resistance and glucose intolerance.
European multicentre trial of
bromocriptine in cyclical mastalgia.
Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to
bromocriptine. Eur J Endocrinol 1996;134:454-456.
Bromocriptine has shown an overall response rate of 75% in two separate double-blind studies.
A retrospective analysis of published cases indicated that the use of
bromocriptine and/or dantrolene appeared to hasten clinical response.
Second-line agents include dopamine agonists (pramipexole, ropinirole, and
bromocriptine) and monoamine oxidase type B (MAO-B) inhibitors (selegiline, rasagiline) (table (16,17)).
The mainstay for treatment of symptomatic hyperprolactinemia, particularly patient's with anovulation, infertility, or galactorrhea, is dopamine agonists, specifically
bromocriptine and carbergoline.